| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H10FN3 |
| Molecular Weight | 262.2716 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[18F]C1=NC=C(C=C1)C2=CC3=C(C=C2)C4=C(N3)C=CN=C4
InChI
InChIKey=GETAAWDSFUCLBS-SJPDSGJFSA-N
InChI=1S/C16H10FN3/c17-16-4-2-11(8-19-16)10-1-3-12-13-9-18-6-5-14(13)20-15(12)7-10/h1-9,20H/i17-1
| Molecular Formula | C16H10FN3 |
| Molecular Weight | 262.2716 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Flortaucipir (18F-AV-1451, also known as 18F-T807) is a highly selective positron emission tomography (PET) imaging agent targeting paired helical filament (PHF)-tau in the brain. This tracer is studying for clinical assessment in patients with various tauopathies, including Alzheimer's disease, as well as in healthy subjects.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Flortaucipir PET images were acquired for 20 min, as four 5-min frames, beginning 80 min after injection of 370 MBq flortaucipir. On a separate day, subjects underwent a florbetapir PET scan for 10 min, as two 5-min frames, beginning 50 min after injection of 370 MBq florbetapir F18.
Route of Administration:
Parenteral
